Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Simvastatin preserves cardiac function in genetically determined cardiomyopathy.

Seena S Abraham1, Juan C Osorio, Shunichi Homma

  • 1Department of Pediatrics, Columbia University, New York, New York, USA.

Journal of Cardiovascular Pharmacology
|April 13, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation, implementation, and impact of an AI model in routine practice for pathologic diagnosis of prostate cancer in an academic medical center.

Journal of pathology informatics·2026
Same author

Induction of adipocyte thermogenic program by Rho-associated coiled-coil containing kinase 2.

iScience·2026
Same author

Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo.

Journal of the American Heart Association·2026
Same author

Endothelial Rho kinase controls blood vessel integrity and angiogenesis.

Cardiovascular research·2025
Same author

Trisomy 15 and monosomy X in a product of conception: a case report.

Laboratory medicine·2025
Same author

Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial.

The Lancet. Neurology·2025

Simvastatin treatment improved cardiac function and reduced apoptosis in heart failure hamsters. This suggests Simvastatin may be a beneficial therapy for heart failure by increasing nitric oxide availability and coronary microvasculature.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Cell Biology

Background:

  • Endothelial dysfunction is a hallmark of heart failure (HF).
  • Simvastatin (Sim) enhances endothelial nitric oxide (NO) production, independent of its lipid-lowering effects.

Purpose of the Study:

  • To investigate the effects of Simvastatin on cardiac function, apoptosis, and nitric oxide (NO) availability in a hamster model of heart failure.

Main Methods:

  • Cardiomyopathic (CM) hamsters received Simvastatin (20 mg/kg) or no treatment for 6 weeks, with age-matched normal hamsters as controls.
  • Cardiac function was assessed using serial echocardiograms.
  • Myocardial apoptosis, endothelial nitric oxide synthase (eNOS), and capillary density were measured.

Main Results:

Related Experiment Videos

  • Simvastatin treatment prevented the decline in left ventricular shortening fraction and increase in left ventricular volume observed in untreated cardiomyopathic hamsters.
  • Myocardial caspase-3 activity and apoptotic nuclear density were altered in Simvastatin-treated hamsters.
  • Myocardial capillary density was significantly higher in the Simvastatin group compared to untreated cardiomyopathic hamsters.

Conclusions:

  • Simvastatin retards heart failure progression in cardiomyopathic hamsters.
  • Potential mechanisms include increased coronary microvasculature, enhanced NO availability, and reduced apoptosis.